title: Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA yoki@mdanderson.org.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oki
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Javier
authors.initials: J
authors.lastname: Knickerbocker
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Felipe
authors.initials: F
authors.lastname: Samaniego
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Loretta
authors.initials: L
authors.lastname: Nastoupil
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Fredrick
authors.initials: F
authors.lastname: Hagemeister
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Romaguera
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Nathan
authors.initials: N
authors.lastname: Fowler
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Larry
authors.initials: L
authors.lastname: Kwak
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.
authors.forename: Jason
authors.initials: J
authors.lastname: Westin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003967:Diarrhea / Q000209:etiology / Q000473:pathology; D004334:Drug Administration Schedule; D004487:Edema / Q000209:etiology / Q000473:pathology; D005221:Fatigue / Q000209:etiology / Q000473:pathology; D005260:Female; D015870:Gene Expression; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D012118:Resorcinols / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: C528044:5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D007555:Isoxazoles; D012118:Resorcinols
keywords: clinical trial; heat shock protein; lymphoma; targeted therapy
references.citation: J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9
references.pmid: 10564678
references.citation: Clin Cancer Res. 2001 Aug;7(8):2228-36
references.pmid: 11489796
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1078-87
references.pmid: 15718306
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1885-93
references.pmid: 15774780
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references.pmid: 15961763
references.citation: Cancer Res. 2008 Apr 15;68(8):2850-60
references.pmid: 18413753
references.citation: Breast Cancer Res. 2008;10(2):R33
references.pmid: 18430202
references.citation: Blood. 2008 Sep 1;112(5):1886-93
references.pmid: 18591380
references.citation: Eur J Haematol. 2010 Apr;84(4):337-44
references.pmid: 20028416
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: Leuk Lymphoma. 2012 May;53(5):990-2
references.pmid: 21988665
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2314-20
references.pmid: 22646928
references.citation: Br J Haematol. 2013 Apr;161(1):57-67
references.pmid: 23356405
references.citation: Clin Cancer Res. 2013 Jul 1;19(13):3671-80
references.pmid: 23757357